Zydus Lifesciences Limited — Updates, 13-08-2025: Press Release

Zydus Lifesciences' formulation manufacturing plant in Ahmedabad has successfully completed a USFDA inspection with NIL observations. This was a Pre-Approval Inspection (PAI) for three products, covering general cGMP. The clean inspection outcome is a major positive, removing regulatory uncertainty for this key facility. It enhances the company's operational stability and paves the way for new product launches, significantly bolstering its prospects in the competitive US pharmaceutical market.